Skip to content

13F-HR filed by BVF INC/IL

BVF INC/IL filed this 13F-HR for the quarter ended 2016-12-31, filed 2017-02-14, with 29 holding rows worth $497,725,000.

Accession
0000921895-17-000368
Filed
2017-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2016

A holdings report, 29 entries on the cover page, a total value of $497,725,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $497,725,000 with VALUE read as thousands by filing date, 13F file number 028-06800. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BLUEPRINT MEDICINES CORP09627Y109COM3,255,280$91,311,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW4,851,691$58,948,000thousands by filing date
CHEMOCENTRYX INC16383L106COM7,798,572$57,709,000thousands by filing date
ARRAY BIOPHARMA INC COM04269X105Stock4,986,186$43,829,000thousands by filing date
CONCERT PHARMACEUTICALS INC206022105COM2,616,249$26,921,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock3,043,805$23,437,000thousands by filing date
FORWARD PHARMA A/S34986J105SPONSORED ADR1,387,853$20,832,000thousands by filing date
CTI BIOPHARMA CORP COM NEW12648L106Stock44,796,940$18,053,000thousands by filing date
COLUCID PHARMACEUTICALS INC19716T101COM484,335$17,630,000thousands by filing date
GLYCOMIMETICS INC38000Q102COM2,826,282$17,240,000thousands by filing date
ONCOMED PHARMACEUTICALS INC COM68234X102Stock1,760,489$13,573,000thousands by filing date
CASCADIAN THERAPEUTICS INC14740B606COM NEW3,133,224$13,504,000thousands by filing date
INFINITY PHARMACEUTICALS INC45665G303COM7,860,808$10,612,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM2,423,300$10,008,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM3,759,398$9,436,000thousands by filing date
ARQULE INC04269E107COM7,400,128$9,324,000thousands by filing date
ESPERION THERAPEUTICS INC NEW COM29664W105Stock712,770$8,924,000thousands by filing date
CHINOOK THERAPEUTICS INC.00739L101Common Stock745,886$8,503,000thousands by filing date
IMMUNE DESIGN CORP.45252L103Common Stock1,320,164$7,261,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK554,806$6,097,000thousands by filing date
GTX INC DEL40052B207COM NEW1,108,433$5,853,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM1,392,720$5,042,000thousands by filing date
NIVALIS THERAPEUTICS INC65481J109COM1,864,474$4,176,000thousands by filing date
OREXIGEN THERAPEUTICS INC686164AB0NOTE 2.750%12/010,000,000$3,000,000thousands by filing dateprincipal
PIERIS PHARMACEUTICALS INC720795103COM1,854,768$2,606,000thousands by filing date
PAIN THERAPEUTICS INC69562K100COM2,278,552$1,299,000thousands by filing date
OREXIGEN THERAPEUTICS INC COM NEW686164302Stock734,976$1,279,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK302,800$1,278,000thousands by filing date
ANTHERA PHARMACEUTCLS INC03674U201Common equity shares62,292$40,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000921895-17-000368this filing2017-02-14acceptance time not in the bulk data set